Zealthy

Provider Profile Name: Zealthy (operating entity: FitRX LLC dba Zealthy)
Website: getzealthy.com
Founded: 2023, headquartered in New York, NY
Founder: Kyle Robertson
Provider Type: Telehealth — Virtual Only
Available In: 34 states
LegitScript Certified: Yes (per company’s own marketing)

Operating Details

• Fully virtual — no in-person visits required
• Membership required; medication costs are separate from the membership fee
• Both insurance and cash-pay pathways available
• HSA/FSA accepted
• No doctor’s referral required

Approach: Zealthy is a physician-supervised telehealth platform that connects patients with licensed clinicians for GLP-1 weight-loss treatment through online consultations and U.S.-licensed pharmacy partners. The platform connects patients with licensed clinicians through secure online consultations and facilitates access to compounded GLP-1 medications through state-licensed U.S. pharmacy partners when clinically appropriate. Zealthy is not a pharmacy, clinic, or drug manufacturer, its role is to facilitate telehealth services while independent medical providers retain full authority over clinical decisions.

About the Company

Zealthy was launched in December 2022 after founder Kyle Robertson left Cerebral, a separate telehealth company that itself faced federal enforcement action. The company is headquartered in New York with approximately 70 employees and has received investment from Ground Up Ventures and Perceptive Ventures.

Zealthy markets itself as one of the more affordable GLP-1 telehealth options in the market, offering both insurance-coordinated brand-name pathways and lower-cost compounded alternatives. The platform’s stated mission is to make GLP-1 treatment accessible with or without insurance, a differentiated model compared to insurance-only platforms like Calibrate.

However, Zealthy’s legal and regulatory history is among the most extensive of any platform in this review series, and prospective patients should understand it fully before enrolling.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

FTC and DOJ Civil Lawsuit — June 2024

On June 10, 2024, the Department of Justice and Federal Trade Commission filed an amended complaint seeking injunctive relief, damages, and penalties against Zealthy Inc., Gronk Inc., Bruno Health P.A., and various executives for allegedly unfair and deceptive privacy, data security, marketing, and billing practices.

The FTC and DOJ accused Zealthy of hiding subscription terms before collecting credit card information, charging recurring fees without obtaining informed consent, and making cancellation unreasonably difficult for users. The complaint also alleged Zealthy shared users’ personal health information with third parties for advertising without informed consent. These violations were alleged under the FTC Act and the Restore Online Shoppers’ Confidence Act (ROSCA).

Two FDA Warning Letters — September 2025 and February 2026

The FDA issued formal warning letters to FitRX LLC, doing business as Zealthy, in September 2025 and again on February 20, 2026. The February 2026 letter cited violations of Sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The FDA concluded that Zealthy’s website contained false or misleading claims about its compounded drug products.

Novo Nordisk Lawsuit — August 2025

Novo Nordisk filed a separate false advertising lawsuit against Zealthy on August 4, 2025, in the Southern District of New York, alleging the company marketed its compounded products as FDA-approved alternatives to brand-name semaglutide medications.

This combination of federal civil enforcement, two FDA Warning Letters, and a pharmaceutical manufacturer lawsuit makes Zealthy’s regulatory exposure among the most significant of any platform in this directory.

GLP-1 Offerings and Weight Loss Services

Zealthy offers both insurance-coordinated brand-name GLP-1 access and a compounded alternative pathway for cash-pay patients.

FDA-Approved Brand-Name Medications (via insurance):

• Wegovy (semaglutide) — FDA-approved for weight loss
• Zepbound (tirzepatide) — FDA-approved for weight loss
• Ozempic and Mounjaro (off-label for weight loss, via insurance)

Compounded Alternatives (cash-pay, when appropriate):

• Compounded semaglutide, which may include glycine (to support muscle preservation) and Vitamin B12 (cyanocobalamin, to help reduce nausea)
• Compounded tirzepatide
• Oral Rybelsus (oral semaglutide) as an FDA-approved alternative for appropriate patients

Zealthy states it does not offer commercially available copies of semaglutide or tirzepatide unless there is an official FDA-declared shortage, a policy commitment that, if maintained, would align with current post-shortage FDA regulations. Whether this stated policy is consistently followed in practice should be verified directly with the assigned provider.

The program includes provider messaging, insurance coordination and prior authorization handling, and weight loss coaching.

Pricing by Type — and What Reviewers Say

Zealthy’s pricing model separates the membership fee from medication costs — a structure that has been a significant source of reviewer confusion and complaint.

Published Pricing:

• Membership: $135/month — includes unlimited access to a medical provider, insurance coordination, and weight loss coaching
• Compounded Semaglutide: from $151/month when purchased quarterly (20% discount applied)
• Compounded Tirzepatide: from $216/month when purchased quarterly
• Brand-name GLP-1s via insurance: approximately $25/month after prior authorization and deductible, per the company’s published estimates
• Insurance coordination included in membership

The total cost for a cash-pay patient using compounded semaglutide, membership plus medication, is approximately $286–$334/month depending on pricing tier, which is at the higher end of the compounded GLP-1 market.

What reviewers say about pricing over time: The billing structure is the single most-cited source of negative feedback across every major review platform. Multiple reviewers describe being charged $135/month for the membership even after canceling, with some reporting charges continuing for 6–12 months post-cancellation. Some reviewers describe Zealthy appearing under different merchant names, including “ZFit,” on their credit card statements after attempting to cancel, which they interpreted as an attempt to avoid chargebacks. One reviewer reported canceling multiple times, using both the app and phone, only to have Zealthy continue charging using a different company name on the charge.

Patients who do successfully use the program and receive medication report largely positive weight loss outcomes.

Reviews from Trustpilot and Google

Zealthy has approximately 5,900 reviews on Trustpilot. The pattern is deeply polarized, similar to Calibrate but with a more pronounced negative tail driven specifically by billing and cancellation issues.

What patients praise:

• Fast prescription approvals — multiple reviewers report same-day or 48-hour turnaround
• Effective weight loss results on injectable formats, with losses of 12 lbs in 6 weeks and similar results cited
• Responsive provider messaging for clinical questions
• Successful insurance coordination — multiple reviewers describe Zealthy successfully navigating prior authorizations and getting brand-name GLP-1s covered at roughly $25/month
• Affordable compounded pricing relative to brand-name retail costs

Common complaints:

• Recurring charges after cancellation — described by a substantial volume of reviewers as ongoing for months or years, with multiple reviewers filing credit card disputes and BBB complaints
• Billing under alternate merchant names (“ZFit,” “GLP1,” “FitRX”) after cancellation, making disputes more difficult to identify and file
• Charges taken before prescription approval — some reviewers report paying before clinical review and not receiving medication or refunds
• Long shipping times and medication not arriving — some reviewers report waiting more than three weeks from sign-up to first order
• Customer service described as difficult to reach, with email as the primary channel and phone support inconsistently available

Compounding Pharmacies Used

Zealthy-sourced compounded drugs are prepared by a state-licensed sterile compounding pharmacy, but the specific pharmacy or pharmacies are not publicly named on the website. Whether Zealthy’s partner pharmacies hold PCAB or NABP accreditation is not disclosed in public-facing materials.

Patients should ask directly which licensed pharmacy will fill their prescription and request a Certificate of Analysis (CoA) for their batch, particularly given the FDA’s February 2026 Warning Letter which cited misleading claims about the compounded products themselves.

Note: Zealthy (FitRX LLC) carries the most extensive regulatory history of any platform in this review series. The company faces an active FTC/DOJ civil lawsuit filed June 2024 for allegedly deceptive billing, subscription, and data practices; two FDA Warning Letters (September 2025 and February 2026) for false or misleading claims about compounded drug products; and a Novo Nordisk false advertising lawsuit filed August 2025. A substantial volume of independent Trustpilot and ConsumerAffairs reviews describe unauthorized charges continuing after cancellation, sometimes under alternate merchant names. Prospective patients should carefully review cancellation terms before enrolling, pay by credit card to enable dispute rights, and verify current legal and regulatory status before beginning treatment. All pricing reflects published rates as of early 2026 and is subject to change. Compounding pharmacy partners are not publicly named.